59
1
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T2079 |
GSK126
GSK2816126A,EZH2 inhibitor |
Histone Methyltransferase | Chromatin/Epigenetic |
GSK126 (GSK2816126A) 是一种选择性的EZH2甲基转移酶抑制剂,IC50为 9.9 nM。 | |||
T6484 |
EI1
KB-145943,Ezh2 inhibitor |
Apoptosis; Histone Methyltransferase | Apoptosis; Chromatin/Epigenetic |
EI1 (Ezh2 inhibitor) 是一种EZH2抑制剂,能够作用于 EZH2 (WT) 和 EZH2 (Y641F),IC50值分别为 15 nM 和 13 nM。 | |||
T7305 |
JQEZ5
|
Histone Methyltransferase | Chromatin/Epigenetic |
JQEZ5 是一种选择性EZH2赖氨酸甲基转移酶抑制剂,具有抗肿瘤作用。它以 SAM 竞争性方式抑制PRC2的酶功能,IC50为 80 nM。 | |||
T12428L |
PF-06726304
|
Histone Methyltransferase | Chromatin/Epigenetic |
PF-06726304 是选择性EZH2有效抑制剂,具有强抗肿瘤生长活性。它抑制野生型和 Y641N 突变型 EZH2,Ki 分别为 0.7 和 3.0 nM。 | |||
T25400 |
EZH2-IN-3
EZH2 inhibitor 3,EZH2-inhibitor-3 |
||
EZH2-IN-3 is an inhibitor of EZH2 and EZH1 with selective impact on diffuse large B cell lymphoma cell growth. | |||
T1788 |
Tazemetostat
E-7438,EPZ6438 |
Histone Methyltransferase | Chromatin/Epigenetic |
Tazemetostat (EPZ6438) 是一种组蛋白甲基转移酶 EZH2 抑制剂 (IC50=11 nM),具有口服活性、选择性和 SAM 竞争性。Tazemetostat 具有抗肿瘤活性,可以用于治疗上皮样肉瘤/滤泡性淋巴瘤。 | |||
T17002 |
Tazemetostat hydrobromide
E-7438 hydrobromide,氢溴酸泰泽司他,EPZ-6438 hydrobromide |
Histone Methyltransferase | Chromatin/Epigenetic |
Tazemetostat hydrobromide (E-7438 hydrobromide) 是口服的EZH2选择性抑制剂。它抑制含有 PRC2 复合体的野生型 EZH2 的活性,Ki 为 2.5 nM。它还抑制 EZH1,IC50为 392 nM。 | |||
T64043 |
EZH2-IN-13
|
Histone Methyltransferase | Chromatin/Epigenetic |
EZH2-IN-13 是一种有效的 EZH2 抑制剂,具有潜在的抗癌活性。EZH2-IN-13 可用于研究与 EZH2 活性相关的疾病。 | |||
T6809 |
CPI-169 racemate
CPI 169,CPI-169,CPI169 |
Epigenetic Reader Domain; Histone Methyltransferase | Chromatin/Epigenetic |
CPI-169 racemate (CPI 169) 是CPI-169的消旋体。CPI-169 是一种有效的选择性 EZH2 抑制剂,对 EZH2 WT、EZH2 Y641N 和 EZH1 的 IC50 分别为 0.24、0.51 和 6.1 nM。 | |||
T67883 |
EZH2-IN-15
SHR2554 |
Histone Methyltransferase | Chromatin/Epigenetic |
EZH2-IN-15 是zeste 2组蛋白修饰增强子(EZH2)的特异性抑制剂。EZH2在许多人类癌症中异常过表达,通过调节Treg 活性来控制适应性反应。肿瘤内EZH2的表达也被证明可以控制先天免疫 | |||
T2435 |
EPZ011989
|
Histone Methyltransferase | Chromatin/Epigenetic |
EPZ011989是一种高选择性可口服的 EZH2抑制剂,对wt EZH2以及EZH2突变型Ki 值<3nM。 | |||
T9700 |
EZH2-IN-2
|
Histone Methyltransferase | Chromatin/Epigenetic |
EZH2-IN-2 是一种 EZH2 抑制剂,IC50 值为 64 nM。EZH2-IN-2 可用于研究与 EZH2 活性相关的癌症或癌前病变。 | |||
T6360 |
3-deazaneplanocin A HCl
|
Others; Histone Methyltransferase | Chromatin/Epigenetic; Others |
3-deazaneplanocin A HCl 是组蛋白甲基转移酶 (EZH2) 和 S-腺苷同型半胱氨酸水解酶 (AHCY) 抑制剂。 | |||
T15194 |
EBI-2511
|
Histone Methyltransferase | Chromatin/Epigenetic |
EBI-2511 是一种高效且具有口服活性的 EZH2 抑制剂,在 Pfeffiera 细胞系中的 IC50值为 6 nM。 | |||
T1775 |
GSK503
|
Histone Methyltransferase | Chromatin/Epigenetic |
GSK503是一种高效特异性EZH2甲基转移酶抑制剂,Ki 值为3到27 nM,具有潜在的抗肿瘤活性。 | |||
T60194 |
N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(N-ethylcyclopropanecarboxamido)-4-methyl-4′-morpholino-[1,1′-biphenyl]-3-carboxamide
|
Histone Methyltransferase | Chromatin/Epigenetic |
N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(N-ethylcyclopropanecarboxamido)-4-methyl-4′-morpholino-[1,1′-biphenyl]-3-carboxamide 是一种强效的、选择性的Enhancer of Zeste Homolog 2 (EZH2),对EZH2 WT 和EZH2-Y641F 的IC50分别为37.6nM 和79.1nM。 | |||
T1905 |
EPZ005687
|
Histone Methyltransferase | Chromatin/Epigenetic |
EPZ005687 是一种选择性EZH2抑制剂,Ki 值为 24 nM,对其选择性是对 EZH1 的 50 倍,对其他 15 种甲基转移酶的 500 倍。 | |||
T12430 |
PF-06821497
|
Histone Methyltransferase | Chromatin/Epigenetic |
PF-06821497 是一种特异性的 EZH2 抑制剂,具有显着的肿瘤生长抑制作用。 | |||
T3057 |
UNC1999
|
Histone Methyltransferase; Autophagy | Autophagy; Chromatin/Epigenetic |
UNC1999 是一种可口服的,选择性和 SAM-竞争性的 EZH2和 EZH1抑制剂,IC50分别为 <10 nM 和 45 nM。 | |||
T8510 |
CPI-1205
Lirametostat |
Histone Methyltransferase | Chromatin/Epigenetic |
CPI-1205 是一种高效的选择性 EZH2 抑制剂(IC50:0.002 μM,EC50:0.032 μM)。 | |||
T6810 |
CPI-360
Synonym 2,CPI 360,CPI360 |
Apoptosis; Histone Methyltransferase | Apoptosis; Chromatin/Epigenetic |
CPI-360是一种小分子EZH2抑制剂(IC50:0.002 μM,EC50: 0.080μM),在EZH200依赖性肿瘤异种移植模型中显示出抗肿瘤活性。 | |||
T6059 |
GSK343
|
Histone Methyltransferase; Autophagy | Autophagy; Chromatin/Epigenetic |
GSK343 是一种特异性且有效的 EZH2 抑制剂,IC50为 4 nM。它对 EZH1 的特异性活性是 60 倍。 | |||
T29231 |
ZLD1039
ZLD-1039,ZLD 1039 |
Histone Methyltransferase | Chromatin/Epigenetic |
ZLD1039 是一种口服有效的、高选择性 EZH2 抑制剂。ZLD1039 高效抑制 EZH2 野生型及 Y641F 和 A677G 突变型,IC50 分别为 5.6、15 和 4.0 nM。ZLD1039 抑制乳腺肿瘤的生长和转移。 | |||
T25471 |
GSK-A
GSK A |
||
GSK-A is a Histone Lysine Methyltransferase EZH2 inhibitor. | |||
T12428 |
PF-06726304 acetate
|
Histone Methyltransferase | Chromatin/Epigenetic |
PF-06726304 acetate is a selective inhibitor of EZH2, with robust antitumor growth activity. | |||
T38827 |
EZH2-IN-5
EZH2-IN-5 |
||
EZH2-IN-5 is a highly effective inhibitor of EZH2, displaying remarkable potency against both wild-type and mutant Tyr641 EZH2, with IC50 values of 1.52 nM and 4.07 nM, respectively. | |||
T40323 |
EZH2-IN-6
EZH2-IN-6 |
||
EZH2-IN-6 is an EZH2 inhibitor with enhanced antitumor activity. | |||
T39497 |
EZH2-IN-4
EZH2-IN-4 |
||
EZH2-IN-4 is a highly potent EZH2 inhibitor that can be taken orally. It exhibits inhibitory effects against wild type (WT) 5-membered (5-mer) EZH2 and mutant 5-mer EZH2, with IC 50 values of 0.923 nM and 2.65 nM, respectively. Moreover, EZH2-IN-4 has demonstrated significant anti-cancer activity. | |||
T39971 |
CPI-1328
|
||
CPI-1328 is an EZH2 inhibitor with a K i value of 63 fM. | |||
T64307 | EZH2-IN-8 | ||
EZH2-IN-8 是一种 EZH2 的有效抑制剂。其中 EZH2 过表达或 SET 区突变 (Y641F、Y641N、A687V、A677G 点突变) 都会造成 H3K27me3 异常升高,诱导多种肿瘤(如乳腺癌、前列腺癌、白血病等)的生长发育。EZH2-IN-8 具有潜力进行癌症疾病的研究。 | |||
T40310 |
PARP/EZH2-IN-1
PARP/EZH2-IN-1 |
||
PARP/EZH2-IN-1 is a novel compound that functions as a dual inhibitor for both PARP (IC50 6.87 nM) and EZH2 (IC50 36.51 nM), showing promising potential for the treatment of triple-negative breast cancer with wild-type BRCA. | |||
T27069 |
CPI-169
CPI 169 (R),CPI-169 (R) |
||
CPI-169 (R) is a novel and potent inhibitor of EZH2. | |||
T25470 |
GSK926
GSK 926,GSK-926 |
||
GSK926 is a selective, SAM-competitive, and cell-active EZH2 inhibitor. | |||
T62896 | EZH2-IN-12 | ||
EZH2-IN-12 (Compound 5) 是一种 EZH2 的有效抑制剂。EZH2-IN-12 具有潜力进行中枢神经系统恶性肿瘤的研究。 | |||
T29232 |
ZLD10A
ZLD 10 A,ZLD-10-A |
||
ZLD10A is a highly potent and selective small molecule inhibitor of EZH2. | |||
T27074 |
CPI-905
CPI 905 |
||
CPI-905 is a potent and selective EZH2 inhibitor with IC50 value of 39.5 nM. | |||
T69771 |
MS-177
|
||
MS177 is an effective and fast-acting EZH2 degrader. MS177 is a PROTAC that consists of a CRBN ligand, linker, and a potent enzymatic EZH2 inhibitor C24 (C24 IC50): 12 nM). MS177 effectively depletes both canonical EZH2–PRC2 and noncanonical EZH2–cMyc complexes. MS177 induces leukaemia cell growth inhibition, apoptosis and cell cycle progression arrest. | |||
T73246 |
EZH2-IN-7
|
||
EZH2-IN-7 是一种有效的EZH2抑制剂。EZH2过表达或 SET 区突变 (Y641F、Y641N、A687V、A677G 点突变) 均导致H3K27me3异常升高,促进多种肿瘤的生长发育,如乳腺癌、前列腺癌、白血病等。EZH2-IN-7 具有研究癌症疾病的潜力。 | |||
T27130 |
DCE_42
DCE 42,DCE42,DCE-42 |
||
DCE_42 is a novel EZH2 inhibitor, it also displays significant anti-proliferation activity against lymphoma cell lines. | |||
T11436 |
GNA002
|
Histone Methyltransferase | Chromatin/Epigenetic |
GNA002 is a highly potent, specific, and covalent EZH2 (Enhancer of zeste homolog 2) inhibitor (IC50: 1.1 μM). | |||
T15240 |
Tazemetostat trihydrochloride
EPZ-6438 trihydrochloride,E-7438 trihydrochloride |
Histone Methyltransferase | Chromatin/Epigenetic |
Tazemetostat trihydrochloride is a selective and orally available inhibitor of EZH2 (IC50: 4 nM for rat EZH2). It inhibits the activity of human PRC2-containing wild-type EZH2 (Ki: 2.5 nM). It inhibits EZH2 (IC50s: 11 and 16 nM in peptide assay and nucleo | |||
T74602 |
PROTAC EZH2 Degrader-1
|
||
PROTACEZH2 Degrader-1 (Compound 150d)是高效的PROTACEZH2降解剂,能够抑制EZH2甲基转移酶的活性,其IC50值为2.7 nM。由于EZH2在许多肿瘤的发生及进展中具有关键作用,这种化合物的研发具有重要意义。 | |||
T69264 |
Aristeromycin diphosphate
|
||
Aristeromycin diphosphate is an inhibitor of S-adenosylhomocysteine hydrolase (AHCY), inducing miR-26a and regulating oncogenic EZH2 expression, showing high inhibitory activity against AHCY, and causing growth inhibition of prostate cancer. | |||
T73116 |
(R)-HH2853
|
||
(R)-HH2853 是一种突变型EZH2抑制剂,对EZH2-Y641F 的IC50<100 nM。(R)-HH2853 可用于癌症和自身免疫性疾病。 | |||
T79849 |
Igermetostat
|
Histone Methyltransferase | Chromatin/Epigenetic |
Igermetostat为EZH2抑制剂,适用于体内外癌症研究。 | |||
T2435L |
EPZ011989 HCl(1598383-40-4 Free base)
EPZ-011989 TFA,EPZ011989 TFA salt,EPZ 011989 TFA,EPZ011989 TFA |
||
EPZ011989为一高效选择性口服EZH2抑制剂,Ki值<3 nM。 | |||
T27129 |
DCE_254
DCE 254,DCE-254,DCE254 |
||
DCE_254 is a novel EZH2 inhibitor, it also displays significant anti-proliferation activity against lymphoma cell lines. | |||
T70588 | Tazemetostat HCl | ||
Tazemetostat HCl is a potent, selective, and orally bioavailable small-molecule inhibitor of EZH2 enzymatic activity. EPZ-6438 induces apoptosis and differentiation specifically in SMARCB1-deleted MRT cells. Treatment of xenograft-bearing mice with EPZ-6438 leads to dose-dependent regression of MRTs with correlative diminution of intratumoral trimethylation levels of lysine 27 on histone H3, and prevention of tumor regrowth after dosing cessation. These data demonstrate the dependency of SMARCB1... | |||
T73134 | EZH2-IN-14 | ||
EZH2-IN-14为一种选择性EZH2(Histone Methyltransferase)抑制剂,具IC50值12 nM。该化合物通过抑制EZH2/PRC2的甲基转移酶活性(减少H3K27me3),显著抑制其功能。相比高度同源的H3K27甲基转移酶EZH1,EZH2-IN-14对EZH2的选择性提高200倍以上。 | |||
T63970 | EZH2-IN-11 | ||
EZH2-IN-11 是 E2HZ 的有效抑制剂。其中 EZH2 的致癌活性已被各种不同癌症类型中的大量研究中证实。EZH2-IN-11 对癌症疾病表现出研究潜力。 |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T8201 |
Gambogenic acid
|
Histone Methyltransferase | Chromatin/Epigenetic |
Gambogenic acid 是黄藤中的一种有效成分,具有抗癌活性。它是特异性EZH2抑制剂,与 EZH2-SET 结构域的 Cys668 位点共价结合,诱导 EZH2 泛素化。 |